DENVER, Colo. (247marketnews.com) -- Liminatus Pharma (NASDAQ:LIMN) has cleared one immediate Nasdaq hurdle, but the clock is still running. The company announced that its common stock transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective August 4, 2026, while the Nasdaq Hearings Panel granted Liminatus additional time to regain compliance with the exchange’s minimum bid price requirement. The new deadline is September 3, 2026, giving the company several more weeks to demonstrate compliance while allowing LIMN to continue trading on Nasdaq under its existing ticker.
The transfer is important because it keeps Liminatus on Nasdaq rather than forcing an immediate delisting, but it should not be confused with a resolution of the bid-price deficiency. The company still must satisfy the applicable minimum bid price requirement by the September 3 deadline, along with other continued-listing requirements. Liminatus said it intends to take the necessary actions to regain compliance during the extension period.
Scott Dam, CFO of Liminatus Pharma, said,“We are pleased to have completed the transfer to the Nasdaq Capital Market and appreciate the Panel providing the Company additional time to demonstrate compliance with the minimum bid price requirement. Maintaining our Nasdaq listing remains an important priority as we continue executing on our corporate and clinical development strategy.”
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.